LPLyonna F. Parise

Lyonna F. Parise

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lyonna F. Parise has a total of 280 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Transcriptional profiles of CD4+ and CD8+ T cells in major depressive disorder

    by Flurin Cathomas, Kenny Chan, Yusuke Shimo, Aarthi Ramakrishnan, Lyonna Parise, Hsiao-Yun Lin, Johana Alvarez, Giada Dirupo, Elizabeth Karpman, Rachel Fisher-Foye, et al.

    Major depressive disorder (MDD) has been associated with peripheral immune alterations, but transcriptional changes within the major T cell lineages remain poorly characterized. We performed bulk RNA sequencing of magnetically-enriched CD4+ and CD8+ T cell fractions from a cohort comprising 81 individuals with MDD and 48 healthy controls (HCs). Differential expression was assessed for protein-coding genes and long noncoding RNAs (lncRNAs), canonical T cell receptor (TCR)-segment transcripts were examined separately, and Ingenuity Pathway Analysis was used to characterize associated molecular pathways and upstream regulators. In CD4-enriched cells, 202 protein-coding genes and lncRNAs met a false discovery rate threshold of < 0.05, whereas no gene met this threshold in CD8-enriched cells. Twenty-one canonical TCR-segment transcripts, predominantly TRAJ genes, were increased in MDD. Pathway analysis implicated broad transcription- and chromatin-regulatory programs. Exploratory sex-stratified analyses identified a broader CD4+ signature in males, comprising 487 differentially expressed genes and including reduced cytotoxic/natural killer-like and major histocompatibility complex class I antigen-processing programs, together with increased TRAJ transcript abundance. These findings identify an MDD-associated peripheral transcriptional signature detected primarily in CD4-enriched cell fractions and characterized by distributed regulatory-state and TCR-segment changes. Together, this dataset provides a cell-type-resolved foundation for future studies examining the clinical relevance and functional consequences of CD4+ T cell transcriptional alterations in MDD.

  • Open Access

    Transcriptional profiles of antidepressant resistance across the corticolimbic pathway of chronically stressed mice

    by Trevonn M. Gyles, Eric M. Parise, Molly Estill, Lyonna F. Parise, Caleb J. Browne, Li Shen, Eric J. Nestler, Angélica Torres-Berrío

    Treatment-resistant depression (TRD), defined by unsuccessful response to multiple antidepressants, affects approximately one-third of individuals with major depressive disorder, yet its underlying molecular mechanisms remain poorly understood. Here, we developed a preclinical model of TRD in which mice exposed to chronic social defeat stress were sequentially treated with fluoxetine (FLX) and ketamine (KET), allowing behavioral stratification into antidepressant responsive and non-responsive mice. RNA sequencing of the nucleus accumbens (NAc) and prefrontal cortex (PFC) revealed transcriptional signatures associated with treatment outcomes. Prior exposure to FLX exerted a priming effect that facilitated molecular and behavioral responsiveness to KET in a subset of animals. However, this priming effect was absent in non-responders, despite identical treatment regimes, suggesting a transcriptional divergence in both the NAc and PFC in underlying differential outcomes. Gene co-expression network analysis identified modules enriched for differentially expressed genes unique to stress-susceptible and FLX-KET nonresponsive mice, as well as modules overlapping with both stress susceptibility and antidepressant resistance. These findings suggest that failed antidepressant treatment can shape the brain’s molecular landscape in a way that influences subsequent treatment outcomes, and that resistance arises not simply from treatment failure but from an absence of adaptive molecular priming. This work provides insight into the gene networks contributing to antidepressant non-response and highlights a mechanistic framework for modeling antidepressant resistance in preclinical systems. By identifying molecular correlates of sequential pharmacological resistance, our findings may inform the development of novel therapeutic strategies for individuals with TRD.


  • Open Access

    A shared transcriptional network in the nucleus accumbens supports resilience to chronic stress across sex

    by Trevonn M. Gyles, Leanne M. Holt, Lyonna F. Parise, Rachel L. Fisher-Foye, Arthur Godino, Caleb J. Browne, Brian T. Kipp, Angelica M. Minier-Toribio, Tamara Markovic, Teagan Daly, et al.

    Although chronic stress increases the risk for depression, only a subset of exposed individuals develop psychiatric illness. The biological mechanisms that protect against depression remain incompletely understood, particularly at the molecular level. Here, we identify a transcriptional network in the nucleus accumbens (NAc), a central brain reward region, that supports stress resilience in both sexes and demonstrate the causal contribution of key hub genes. Using chronic social defeat stress, RNA-seq, and co-expression network analysis, we find sex-specific but overlapping gene modules linked to resilience, anchored by shared hub genes embedded within a common network architecture. Overexpression of these hub genes in stress-naive mice confers stress protection and induces a transcriptional state that is discrete from both susceptible and resilient profiles. These findings position resilience as a structured and targetable molecular phenotype and provide a basis for investigating sex-informed mechanisms of stress adaptation.

  • Top Cited Papers

    Major depressive disorder shares systemic immune signatures and potential therapeutic targets with inflammatory skin diseases

    by Helen He, Flurin Cathomas, Lyonna F. Parise, Eden David, Mina Rizk, Kelly Hawkins, Elizabeth Karpman, Scott J. Russo, Emma Guttman, James W. Murrough

    Major depressive disorder (MDD) is a prevalent neuropsychiatric disorder associated with significant morbidity and mortality. Increasing evidence suggests that a subset of MDD patients exhibit a dysregulated immune system. However, few clinical studies have tested the efficacy of anti-inflammatory drugs in reducing symptoms of depression. In contrast, targeted immunomodulatory drugs have revolutionized the treatment of inflammatory skin disorders, such as atopic dermatitis (AD) and psoriasis. To assess the viability of a targeted treatment approach in MDD, we first compared the blood proteomic profiles of patients with MDD to those of patients with AD, psoriasis, and healthy controls (HCs). We demonstrated that the proteomic signatures of MDD patients share Th2 skewing and dysregulation of other immune/neurovascular-related proteins with AD. Next, we performed an in-silico drug repurposing analysis to test whether common biologics used in dermatology could also affect the dysregulated proteomic signature observed in MDD patients. This computational approach identified dupilumab, which targets the IL-4 receptor α subunit (IL-4Rα) and thus inhibits the Th2 axis, as significantly affecting the MDD signature by reversing the dysregulation of several inflammatory proteins related to Th2 signaling. Finally, in a mouse model of chronic social defeat stress (CSDS), we showed that pharmacological inhibition of IL-4Rα prevented stress-induced social avoidance behavior. Our findings underscore the potential role of the Th2 axis in MDD, highlighting the potential of specifically targeting Th2 as a disease-modifying treatment. Additionally, the back-translational drug repurposing strategy employed in this study may offer a novel approach to identify immunomodulatory drugs in psychiatry.


  • Open Access

    Stress drives myelopoiesis to impair atherosclerosis resolution

    by Edward Fisher, Ozlem Tufanli, Bianca Scolaro, Giovanni Civieri, Florencia Schlamp, Sofie Delbare, Ada Weinstock, Flurin Cathomas, Stephanie Pena, Angélica Torres Berrío, et al.

    Atherosclerotic cardiovascular diseases (ASCVD) remain the leading cause of death globally. Animal and human studies link psychological stress-related disorders to ASCVD. Despite this accumulating evidence linking stress to increased cardiovascular disease (CVD) risk, it remains unclear whether stress impairs the benefits of standard risk-reduction therapies, of which lipid-lowering remains the most common, or whether this increased risk is driven by systemic inflammatory states. We tested the hypothesis that psychological stress limits the benefits of lipid lowering on resolving inflammation in atherosclerotic plaques by combining two established mouse models, namely one in which levels of atherogenic LDL cholesterol (LDL-C) can be lowered after plaques develop, and the other a model of chronic social defeat stress (CSDS). Here we show that mice susceptible to CSDS (“SUS”) had attenuated benefits of LDL-C lowering compared to control (CON) or resilient (RES) mice. Moreover, in SUS mice (vs. CON or RES) there was heightened inflammation in the plaque macrophages, with evidence that this was a result of re-programming in the bone marrow (BM) of the precursors of macrophages, namely monocytes. Remarkably, these observations aligned with human imaging studies, in which LDL-C lowering therapy was not as effective in reducing either systemic or arterial inflammation in subjects with higher (vs. lower) neural imaging measures of psychological stress. In summary, the integration of the mouse model and human data provides important mechanistic and clinical insights into the crucial role of chronic stress in ASCVD, highlighting that this common risk factor impairs the anti-atherosclerotic benefits of lipid-lowering medications and may represent an important determinant of residual ASCVD risk.


  • Open Access

    Design and validation of novel brain-penetrant HCN channel inhibitors to ameliorate social stress-induced susceptible phenotype

    by Emily M. Teichman, Jianping Hu, Hsiao-Yun Lin, Rachel L. Fisher-Foye, Anthony Blando, Xiaoping Hu, H. Ümit Kaniskan, Sarah E. Montgomery, Min Cai, Lyonna F. Parise, et al.

    Major Depressive Disorder (MDD) is a devastating, multifactorial disease with limited pharmacological treatment options. Patients with MDD exhibit alterations in their dopamine (DA) signaling pathways through the midbrain ventral tegmental area (VTA). A similar observation is also detected in preclinical models of stress - mice exhibit behavioral and physiological impairments following chronic social defeat stress (CSDS). Prior studies demonstrate that CSDS-susceptible mice have increased VTA DA neuronal excitability, in part driven by an upregulation in hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels. Inhibiting HCN channels with known inhibitors such as Cilobradine alleviates the negative behavioral effects of CSDS. Here, we aimed to identify Cilobradine analogs with improved neural tropism and inhibitory efficacy. Two compounds, MS7710 and MS7712, differing by their left-hand side moieties, have a similar, potent inhibitory effect on VTA DA Ih currents as compared to Cilobradine, and a greater inhibitory effect than Cilobradine on VTA DA firing rate. We demonstrate that MS7710 and MS7712 have superior brain/plasma concentration ratios as compared to Cilobradine. They were efficacious at inhibiting VTA DA neuron firing rate and bursting activity in CSDS-susceptible male mice at lower doses than Cilobradine, which was recapitulated in female CSDS-susceptible mice with MS7710. Finally, we define that a single intraperitoneal injection of MS7710 ameliorates CSDS-induced social interaction deficits and reward-associated cognitive inflexibility for at least two weeks in male and female mice. These findings yield a novel HCN channel inhibitor with improved neural tropism and stress-alleviating effects that could provide a basis for future antidepressant drug discovery.


  • Open Access

    A crucial role for the cortical amygdala in shaping social encounters

    by Antonio V. Aubry, Romain Durand-De Cuttoli, Elizabeth Karpman, Rachel L. Fisher-Foye, Lyonna F. Parise, Flurin Cathomas, C. Joseph Burnett, Yewon Yang, Chongzhen Yuan, Alexa R. LaBanca, et al.

    Aggression is an evolutionarily conserved behaviour that controls social hierarchies and protects valuable resources. In mice, aggressive behaviour can be broken down into an appetitive phase, which involves approach and investigation, and a consummatory phase, which involves biting, kicking and wrestling1. Here, by performing an unsupervised weighted correlation network analysis on whole-brain FOS expression in mice, we identify a cluster of brain regions, including hypothalamic and amygdalar subregions and olfactory cortical regions, that are highly co-activated in male but not in female aggressors. The posterolateral cortical amygdala (COApl)—an extended olfactory structure—was found to be a hub region, on the basis of the number and strength of correlations with other regions in the cluster. Our data also show that oestrogen receptor 1 (Esr1)-expressing cells in the COApl (COAplEsr1) exhibit increased activity during attack behaviour and during bouts of investigation that precede an attack, in male mice only. Chemogenetic or optogenetic inhibition of COAplEsr1 cells in male aggressors reduces aggression and increases pro-social investigation without affecting social reward and reinforcement behaviour. We further show that COAplEsr1 projections to the ventromedial hypothalamus and central amygdala are necessary for these behaviours. Collectively, these data suggest that, in aggressive males, COAplEsr1 cells respond specifically to social stimuli, thereby enhancing their salience and promoting attack behaviour.


  • Open Access

    Astrocyte-derived extracellular matrix proteins regulate synapse remodeling in stress-induced depression

    by Ran Zhang, Patricia Rodriguez-Rodriguez, Lucian Medrihan, Jerry C. Chang, Tatiana Ferraro, Pedro Del Cioppo Vasques, Wei Wang, Caroline Menard, Flurin Cathomas, Kenny L. Chan, et al.

    Major depressive disorder (MDD) is a common mood condition affecting multiple brain regions and cell types. Changes in astrocyte function contribute to depressive-like behaviors. However, while neuronal mechanisms driving MDD have been studied in some detail, molecular mechanisms by which astrocytes promote depression have not been extensively explored. To uncover astrocyte contributions to MDD, we subjected male mice to chronic social defeat stress precipitated by encounters with a dominant male. Animals exposed to this treatment exhibit symptoms indicative of MDD, including reduced social interactions, anxiety, despair, and anhedonia. We then measured astrocyte translating mRNA expression changes in mice that underwent chronic social defeat and control animals using ribosome affinity purification. Bioinformatic analyses reveal significant alterations in the prefrontal cortex (PFC), consistent with previous studies implicating this brain region in MDD. Expression of genes encoding extracellular matrix (ECM) proteins, cell-cell interaction proteins, and proteins controlling glutamatergic synaptic function are significantly altered. These changes correlate with perturbation of glutamatergic transmission, measured by electrophysiology, and increased synaptic cleft size. Among ECM genes, increased expression of mRNA encoding the synaptic remodeling protein s ecreted p rotein a cidic and r ich in c ysteine ( Sparc ) correlates the most with the depressive phenotype. Furthermore, presence of SPARC and other ECM proteins in synaptosomes is also increased and overexpressing Sparc in PFC partially alleviates stress symptoms. Our results raise the possibility that increased expression of Sparc may be a natural protective mechanism against stress-induced synaptic dysfunction in depression.


  • Open Access

    ERK2 Signaling in the Nucleus Accumbens Facilitates Stress Susceptibility and Cocaine Reinstatement

    by Lyonna F. Parise, Sergio D. Iñiguez, Brandon L. Warren, Eric M. Parise, Ryan K. Bachtell, David M. Dietz, Eric J. Nestler, Carlos A. Bolaños-Guzmán


  • Top Cited Papers

    Structural pharmacology and therapeutic potential of 5-methoxytryptamines

    by Audrey L Warren, David Lankri, Michael J Cunningham, Inis C Serrano, Lyonna F Parise, Andrew C Kruegel, Priscilla Duggan, Gregory Zilberg, Michael J Capper, Vaclav Havel, et al.

    Psychedelic substances such as lysergic acid diethylamide (LSD) and psilocybin show potential for the treatment of various neuropsychiatric disorders1,2,3. These compounds are thought to mediate their hallucinogenic and therapeutic effects through the serotonin (5-hydroxytryptamine (5-HT)) receptor 5-HT2A (ref. 4). However, 5-HT1A also plays a part in the behavioural effects of tryptamine hallucinogens5, particularly 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), a psychedelic found in the toxin of Colorado River toads6. Although 5-HT1A is a validated therapeutic target7,8, little is known about how psychedelics engage 5-HT1A and which effects are mediated by this receptor. Here we map the molecular underpinnings of 5-MeO-DMT pharmacology through five cryogenic electron microscopy (cryo-EM) structures of 5-HT1A, systematic medicinal chemistry, receptor mutagenesis and mouse behaviour. Structure–activity relationship analyses of 5-methoxytryptamines at both 5-HT1A and 5-HT2A enable the characterization of molecular determinants of 5-HT1A signalling potency, efficacy and selectivity. Moreover, we contrast the structural interactions and in vitro pharmacology of 5-MeO-DMT and analogues to the pan-serotonergic agonist LSD and clinically used 5-HT1A agonists. We show that a 5-HT1A-selective 5-MeO-DMT analogue is devoid of hallucinogenic-like effects while retaining anxiolytic-like and antidepressant-like activity in socially defeated animals. Our studies uncover molecular aspects of 5-HT1A-targeted psychedelics and therapeutics, which may facilitate the future development of new medications for neuropsychiatric disorders.